Cenegermin shows high efficacy in Chinese patients with neurotrophic keratopathy

Cenegermin eye drops are effective and generally well-tolerated for treating stage 2/3 neurotrophic keratopathy in Chinese patients, with a high rate of corneal healing maintained over 1 year and mostly mild or moderate side effects, according to a study.

In the Phase 4, multicenter trial, 28 patients with neurotrophic keratopathy received cenegermin (20 mcg/mL) 6 times daily for 8 weeks, with follow-up through week 56. By week 8, 84.6% of patients achieved corneal healing, and most maintained recovery at 1 year, with only a small proportion experiencing lesion recurrence.

Treatment-emergent adverse events were reported in 89.3% of patients, mostly mild or moderate, with eye pain being the most common drug-related effect. No serious adverse events were linked to the therapy or required discontinuation.

The study supports cenegermin as an effective treatment option for Chinese patients with moderate to severe NK, aligning with its established use in U.S. and European populations.

Reference
Li S, Xu J, Yuan J, et al. Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China. Ophthalmol Ther. 2025;doi: 10.1007/s40123-025-01253-5. Epub ahead of print. PMID: 41046317.